Corporate Updates

Care Hospitals’ Relisys Aims High

The promoters have so far infused Rs 40 crore in the medical equipment business through equity and have invested another Rs 30 crore through debt.


Hyderabad: Care Hospitals is now planning to ramp up their medical devices business,Relisys Medical Devices.The promoters, led by Dr. N Krishna Reddy, are now closing in on a deal to tap strategic or private equity funding for Relisys.

Relisys Medical Devices specialises in manufacturing cardiac stents and catheters and is among the few Indian companies which manufactures these key medical devices entirely in India, starting from the raw materials. Dr. N. Krishna Reddy is said to be raising funding to the tune of Rs 40 crore for the next phase of commercialisation of technology.

For the past few years, we have been incubating the technology and now we are ready for commercialisation to take the product to the global stage, Reddy said.


The promoters have so far infused Rs 40 crore through the equity route and have invested another Rs 30 crore through debt.

The medical devices sector in India is now evolving rapidly and it has to grow similarly like how the pharma sector grew from bulk to formulations, Reddy added.

Relisys products are already being used at many hospitals in India including atFortis,Max, Jayadeva, Care Hospitals besides being exported to few countries including to Turkey. The company has set up a manufacturing unit spread over 160,000 square feet spread across 7.5 acres, which has the capability to churn out stents and catheters right from granule stage.

Relisys move to tap external funding comes at a time when the Indian market is growing a rapid pace from the current consumption of close to 200,000 stents per year.

Globally, the market is valued at close to $10 billion with global majors such as Abbot, Medtronic controlling major share of the market.

Follow and connect with us on Facebook, Twitter, LinkedIn, Elets video

Eletsonline News

Follow us on

Most Popular

200000+ Subscribers read it every day.
Subscribe Newsletter
To Top